New strategy for breast cancer treatment: Neoribocic inhibits tumor proliferation through cell cycle blockade

As one of the most common malignant tumors in the world, breast cancer is still a major challenge to human health despite the continuous improvement of treatment methods. Therefore, it is of great clinical significance to develop new anti-breast cancer drugs to improve the therapeutic effect. As a CDK4/6 inhibitor, Ribociclib has shown potential in breast cancer treatment. Based on this, we designed and synthesized a new type of ribocyclib derivative Neoribocic, and deeply studied its role mechanism in breast cancer. Research results show that Neoribocic can significantly inhibit the proliferation, migration and invasion ability of breast cancer cells in in vitro experiments, and show excellent anti-tumor activity. By analyzing MDA-MB-231 cells treated with Neoribocic through RNA sequencing (RNA-Seq), we found that Neoribocic may block the progression of breast cancer cells in the G2/M stage by activating the p53 signaling pathway, thus exerting their anti-tumor effect. . In addition, in vivo experiments further confirm that Neoribocic can not only effectively inhibit tumor growth, but also significantly inhibit the angiogenesis in the chicken embryonic cyst membrane, suggesting that it may have an anti-angiogenesis effect. In order to investigate the role and mechanism of Neoribocic in Breast Cancer, we treated MDA-MB-231 cells with Neoribocic and without treatment. Then, we performed gene expression profiling analysis using RNA seq data from Neoribocic and DMSO cells.